ASX: RCE

$0.0

ASX: RCE

$0.0

ASX: RCE

$0.0

Recce Pharmaceuticals advances anti-infective development and clinical trials in FY23

Posted on by recce_com
alt="Recce R327 vial"

Recce Pharmaceuticals advances anti-infective development and clinical trials in FY23

Quick Links

About Us

Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.

Stay up to date

Receive news and information direct to your inbox.
Twitter Linkedin-in Youtube

© 2024 Recce Pharmaceuticals